TABLE 1.
Patient characteristics at baseline.
| N | 17 |
| Age (years), median (IQR) | 13 (11–20) |
| Gender (male), n (%) | 9 (52.9) |
| Sweat test (Cl- mEq/L), mean (SD) | 95.2 (20) |
| CFTR genotype, n (%) | |
| ΔF508-homozygous | 3 (17.6) |
| ΔF508-heterozygous | 12 (70.6) |
| Other mutation | 2 (11.7) |
| FEV1% predicted, mean (SD) | 90.6 (20.5) |
| FVC% predicted, mean (SD) | 92.9 (19.1) |
| FEV1/FVC%, mean (SD) | 91.9 (12.3) |
| Use of nebulized antibiotic during the previous year (>1 month), n (%) | 1 (5.9) |
| Exacerbations in the previous year, median (IQR) | 1 (0–1) |
IQR, interquartile range; SD, standard deviation; CFTR, Cystic fibrosis transmembrane conductance regulator.